- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06835556
Volatiliteit in paranoia (VIP)
Het testen van de rol van overtuiging bijwerken bij vervolgingswaanideeën
The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals with schizophrenia-spectrum disorders.
The main questions are:
- do prior expectations about environmental volatility reduce following effective psychotherapeutic treatment of delusions?
- does corresponding brain activity related to volatility change with effective treatment of delusions?
Participants will:
- engage in CBTp or TAU + phone check-ins for 16 weeks
- complete assessments at 4 timepoints over the course of 6 months
- complete an MRI when possible
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Julia Sheffield, PhD
- Telefoonnummer: 615-343-3839
- E-mail: julia.sheffield@vumc.org
Studie Locaties
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37212
- Werving
- Vanderbilt University Medical Center
-
Contact:
- Julia Sheffield, PhD
- Telefoonnummer: 615-343-3839
- E-mail: julia.sheffield@vumc.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Men and women age 18 - 65.
- Communicative in English.
- Premorbid IQ >79 (WTAR)
- Provide voluntary, written informed consent.
- Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.
- Diagnosis of a non-affective psychotic disorder (e.g. schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder)
- A persecutory delusion scoring at least a 3 on the conviction scale of the Psychotic Symptoms Rating Scale (PSYRATS) that had persisted for at least two months and that was not considered the direct result of substance use.
Exclusion Criteria:
- Serious medical or neurological illness known to interfere with cognitive functioning (uncontrolled/unstable diabetes, uncontrolled hypothyroidism, Cushing's disease, Lupus, any demyelinating disease such as Multiple Sclerosis, HIV infection, CNS infection, unstable heart disease, active hepatitis, other significant endocrine condition, any cancer involving the CNS/brain, any uncorrected vision problems, tardive dyskinesia).
- History of severe head trauma with loss of consciousness >30 minutes.
- Primary diagnosis of alcohol or substance use disorder or personality disorder
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CBTp
Weekly individual psychotherapy targeting specific maintenance factors of paranoia (worry, anomalous experiences, self-confidence, and safety behaviors), tailored to the participant's experience |
Individuals will be assessed for which psychological factors are maintaining paranoia in their daily lives. They will collaboratively identify one maintenance factor to focus on (e.g. worry, anomalous experience, self-confidence, PTSD) for 8 weeks of individual therapy. Then, all participants will transition to 8 weeks of individual therapy focused on dropping safety behaviors and re-engaging in everyday life. |
|
Actieve vergelijker: TAU + Phone Check-In
Participants will continue with their regular care (treatment as usual (TAU)) without interference from the study team. In addition to TAU, a study therapist will call them weekly to review what treatment the participants have engaged in. Phone calls will last approximately 5-10 minutes |
Individuals will continue treatment as usual (TAU). In addition they will have contact with a study therapist weekly via phone to provide information on what treatment they received. Phone check-ins will last approximately 5-10 minutes. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in prior expectations of volatility (mu3)
Tijdsspanne: Baseline to 16 weeks
|
Reversal learning data will be collected from a 3-option probabilistic reversal learning task. This data will be analyzed using a computational model that estimates the prior expectations of environmental volatility. That parameter, in many models, is Mu3. |
Baseline to 16 weeks
|
|
Change in unexpected uncertainty (kappa)
Tijdsspanne: Baseline to 16 weeks
|
Reversal learning data will be collected from a 3-option probabilistic reversal learning task. This data will be analyzed using a computational model that estimates the unexpected uncertainty, sometimes also referred to as sensitivity to volatility. |
Baseline to 16 weeks
|
|
Change in psychotic Symptom Rating Scale (PSYRATS)- Belief Subscale Total
Tijdsspanne: Baseline to 16 weeks
|
The PSYRATS is a interview-assisted assessment measuring the severity of a delusional belief. Total scores range from 0-24 with high scores indicating more severe delusion; 6 questions, 0-4 scale for each item |
Baseline to 16 weeks
|
|
Change in PANSS Positive Symptoms - Total
Tijdsspanne: Baseline to 16 weeks
|
The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The positive symptom total score is the sum of the Positive Symptom items |
Baseline to 16 weeks
|
|
BOLD activation change during PRL task, pre/post treatment - prefrontal cortex
Tijdsspanne: Baseline to 16 weeks
|
functional MRI will be used to collect BOLD activation data during the PRL reversal learning task. The investigators expect changes in activation following treatment, particularly in the CBTp group |
Baseline to 16 weeks
|
|
BOLD activation change pre/post treatment - striatum
Tijdsspanne: Baseline to 16 weeks
|
functional MRI will be used to collect BOLD activation data during the PRL reversal learning task. The investigators expect changes in activation following treatment, particularly in the CBTp group |
Baseline to 16 weeks
|
|
BOLD activation change during PRL task, pre/post treatment - locus coeruleus
Tijdsspanne: Baseline to 16 weeks
|
functional MRI will be used to collect BOLD activation data during the PRL reversal learning task. The investigators expect changes in activation following treatment, particularly in the CBTp group |
Baseline to 16 weeks
|
|
Task-based functional connectivity changes during PRL task, pre/post treatment - prefrontal cortex to striatum
Tijdsspanne: Baseline to 16 weeks
|
Functional connectivity during the PRL task will be quantified between the dlPFC and striatum |
Baseline to 16 weeks
|
|
Volatility Expectations - During Stable3 Task
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Scale of Unpredictability Beliefs
Tijdsspanne: Change from baseline
|
Change from baseline
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Vetgedrukte activeringswijzigingen tijdens PRL -taak, pre/post -behandeling - gehele hersenanalyse
Tijdsspanne: Basislijn tot 16 weken
|
Basislijn tot 16 weken
|
|
|
Change in PANSS P1 Item
Tijdsspanne: Baseline to 16 weeks
|
The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. P1 is the first item on the scale, representing delusion severity |
Baseline to 16 weeks
|
|
Change in PANSS P6 Item
Tijdsspanne: Baseline to 16 weeks
|
The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. P6 is the item on the scale assessing severity of paranoia/suspiciousness |
Baseline to 16 weeks
|
|
Change in meta-volatility learning rate (omega3)
Tijdsspanne: Baseline to 16 weeks
|
Reversal learning data will be collected from a 3-option probabilistic reversal learning task. This data will be analyzed using a computational model that estimates the meta-volatility. |
Baseline to 16 weeks
|
|
PSYRATS Hallucinations
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Kamin Blocking
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Social Hallucinations - Chasing
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Minnesota Trust Game
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
r-GPTS
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
DWQ
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
BDI-II
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
O-AS
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Positive Thoughts Scale
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Guilt and Shame Experiences Scale
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
O-CDQ
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Insomnia Severity Index
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
PCL-5
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
CEFSA
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
DERS-16
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
Intolerance of Uncertainty
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
LSAS
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
LSNS-6
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
CHOICE
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
WEMWBS
Tijdsspanne: Change from baseline
|
Change from baseline
|
|
|
MCQ-36
Tijdsspanne: Change from baseline
|
Change from baseline
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 240788
- R01MH137024 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .